Myocardial ischemia–reperfusion injury is more severe during the sleep-to-wake transition period of the day. A new study shows that timed administration of digoxin, a cardiac glycoside approved by the US Food and Drug Administration, prevents experimental myocardial ischemia–reperfusion injury by controlling proteostasis of the circadian-clock regulator Rev-Erbα.
This is a preview of subscription content, log in via an institution to check access.
References
Hausenloy, D. J. & Yellon, D. M. Nat. Rev. Cardiol. 13, 193–209 (2016).
Heusch, G. Nat. Rev. Cardiol. 17, 773–789 (2020).
Montaigne, D. et al. Lancet 391, 59–69 (2018).
Cho, H. et al. Nature 485, 123–127 (2012).
Prassas, I. & Diamandis, E. P. Nat. Rev. Drug Discov. 7, 926–935 (2008).
Marck, P. V. & Pierre, S. V. Int. J. Mol. Sci. 19, 2336 (2018).
Vinod, M. et al. Nature Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00148-z (2022).
Zhao, X. et al. Cell 165, 1644–1657 (2016).
DeBruyne, J. P., Baggs, J. E., Sato, T. K. & Hogenesch, J. B. Proc. Natl Acad. Sci. USA 112, 12420–12425 (2015).
Ong, S.-G. et al. Cardiovasc. Res. 104, 24–36 (2014).
Nakayama, K. et al. Cell 117, 941–952 (2004).
Peek, C. B. et al. Cell Metab. 25, 86–92 (2017).
Aoyama, T. et al. Circulation 111, 1652–1659 (2005).
Zhang, L. et al. JCI Insight 2, e95177 (2017).
Busonero, C. et al. Cancers (Basel) 12, 3840 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Wang, H.J., Evans, R.M. Timed use of cardiac glycoside protects the heart. Nat Cardiovasc Res 1, 973–975 (2022). https://doi.org/10.1038/s44161-022-00158-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-022-00158-x
- Springer Nature Limited